FDA panel backs Astellas drug for invasive fungal infections
January 22, 2015 at 14:16 PM EST
Jan 22 (Reuters) - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's isavuconazonium for the treatment of rare, often fatal invasive fungal infections that can hit patients with blood cancers.
